Synthetic Cannabinoid Drug For Covid-19 Approved For Phase-1 Clinical Trials

Now, a synthetic cannabinoid drug, ARDS-003, has been given approval by the FDA to begin phase-1 clinical trials.

ARDS-003 is an injectable drug designed to help with acute respiratory distress syndrome (ARDS), a serious syndrome that occurs in severe cases of the novel coronavirus.